Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma

Experimental Cell Research

Volumn 315, Issue 19, 2009, Pages 3281-3293

  Lajmanovich, Alicia ^a,b,c   Ribeyron, Juliana Bruder ^a,b,c   Florin, Anne ^a,b,d   Fournier, Alexandra ^a,b   Pasquier, Marie Anne ^a,b   Duley, Samuel ^a,b   Chauvet, Martine ^d   Plumas, Joel ^a,b   Bonnefoix, Thierry ^a,b   Gressin, Remy ^a,b,c   Leroux, Dominique ^a,b,d   Callanan, Mary B ^a,b,d  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d Molecular and Cellular Haematology Unit Plateforme de genetique moleculaire des tumeurs   (France)

Author keywords

CD40 activation; CD95 apoptosis; CD95 mRNA splicing; Malignant lymphoma; Mitochondrial death pathway

Indexed keywords

CASPASE 3; CASPASE 9; CD40 ANTIGEN; CYCLOHEXIMIDE; FAS ANTIGEN; PROTEIN BID; RNA;

ALTERNATIVE RNA SPLICING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; MITOCHONDRION; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RNA SPLICING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 70350617657     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.09.008     Document Type: Article

References (54)

1. Hennino A., Berard M., Casamayor-Palleja M., Krammer P.H., and Defrance T. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J. Immunol. 165 (2000) 3023-3030
2. Feig C., Tchikov V., Schutze S., and Peter M.E. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26 (2007) 221-231
3. French L.E., and Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin. Cancer Biol. 12 (2002) 51-55
4. Bremer E., van Dam G., Kroesen B.J., de Leij L., and Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends. Mol Med. 12 (2006) 382-393
5. Barnhart B.C., and Peter M.E. The TNF receptor 1: a split personality complex. Cell 114 (2003) 148-150
6. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev., Mol. Cell Biol. 9 (2008) 47-59
7. Troeger A., Schmitz I., Siepermann M., Glouchkova L., Gerdemann U., Janka-Schaub G.E., Schulze-Osthoff K., and Dilloo D. Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. Blood 110 (2007) 384-387
8. Q. Li, K. Tsuruda, K. Sugahara, N. Dateki, E. Ohishi, Y. Yamada, M. Tomonaga, H. Moriuchi, Y. Tsuji, S. Kamihira, Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells, Leuk. Res.24 (5) (2000) 437-444.
9. Shen L., Liang A.C., Lu L., Au W.Y., Kwong Y.L., Liang R.H., and Srivastava G. Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. Am. J. Pathol. 161 (2002) 2123-2131
10. Takahashi H., Feuerhake F., Kutok J.L., Monti S., Dal Cin P., Neuberg D., Aster J.C., and Shipp M.A. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin. Cancer Res. 12 (2006) 3265-3271
11. Traverse-Glehen A., Verney A., Baseggio L., Felman P., Callet-Bauchu E., Thieblemont C., Ffrench M., Magaud J.P., Coiffier B., Berger F., and Salles G. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia 21 (2007) 1821-1824
12. van Doorn R., Dijkman R., Vermeer M.H., Starink T.M., Willemze R., and Tensen C.P. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res. 62 (2002) 5389-5392
13. Gronbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K., Hansen N.E., Zeuthen J., Hou-Jensen K., and Guldberg P. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92 (1998) 3018-3024
14. Wohlfart S., Sebinger D., Gruber P., Buch J., Polgar D., Krupitza G., Rosner M., Hengstschlager M., Raderer M., Chott A., and Mullauer L. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am. J. Pathol. 164 (2004) 1081-1089
15. Muschen M., Rajewsky K., Kronke M., and Kuppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 23 (2002) 75-80
16. Holzelova E., Vonarbourg C., Stolzenberg M.C., Arkwright P.D., Selz F., Prieur A.M., Blanche S., Bartunkova J., Vilmer E., Fischer A., Le Deist F., and Rieux-Laucat F. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N. Engl. J. Med. 351 (2004) 1409-1418
17. Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Rosen-Wolff A., Peters A.M., Sneller M.C., Hallahan C.W., Wang J., Fischer R.E., Jackson C.M., Lin A.Y., Baumler C., Siegert E., Marx A., Vaishnaw A.K., Grodzicky T., Fleisher T.A., and Lenardo M.J. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98 (2001) 194-200
18. Liu J.H., Wei S., Lamy T., Li Y., Epling-Burnette P.K., Djeu J.Y., and Loughran Jr. T.P. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 100 (2002) 1449-1453
19. Kamihira S., Yamada Y., Tomonaga M., Sugahara K., and Tsuruda K. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis. Br. J. Haematol. 107 (1999) 851-860
20. Siegel R.M., Frederiksen J.K., Zacharias D.A., Chan F.K., Johnson M., Lynch D., Tsien R.Y., and Lenardo M.J. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288 (2000) 2354-2357
21. Cascino I., Papoff G., De Maria R., Testi R., and Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156 (1996) 13-17
22. Cascino I., Fiucci G., Papoff G., and Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154 (1995) 2706-2713
23. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., and Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263 (1994) 1759-1762
24. Roesler J., Izquierdo J.M., Ryser M., Rosen-Wolff A., Gahr M., Valcarcel J., Lenardo M.J., and Zheng L. Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3′ splice site AG in CD95 intron 5 on one allele. Blood 106 (2005) 1652-1659
25. Irisarri M., Plumas J., Bonnefoix T., Jacob M.C., Roucard C., Pasquier M.A., Sotto J.J., and Lajmanovich A. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia 14 (2000) 2149-2158
26. Oyarzo M.P., Medeiros L.J., Atwell C., Feretzaki M., Leventaki V., Drakos E., Amin H.M., and Rassidakis G.Z. c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 107 (2006) 2544-2547
27. Uherova P., Olson S., Thompson M.A., Juskevicius R., and Hamilton K.S. Expression of c-FLIP in classic and nodular lymphocyte-predominant Hodgkin lymphoma. Appl. Immunohistochem. Mol. Morphol. 12 (2004) 105-110
28. Hennino A., Berard M., Krammer P.H., and Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J. Exp. Med. 193 (2001) 447-458
29. Daniel P.T., and Krammer P.H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152 (1994) 5624-5632
30. Lagresle C., Bella C., Daniel P.T., Krammer P.H., and Defrance T. Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule. J. Immunol. 154 (1995) 5746-5756
31. Garrone P., Neidhardt E.M., Garcia E., Galibert L., van Kooten C., and Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 182 (1995) 1265-1273
32. Willimott S., Baou M., Naresh K., and Wagner S.D. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br. J. Haematol. 138 (2007) 721-732
33. Dicker F., Kater A.P., Fukuda T., and Kipps T.J. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 105 (2005) 3193-3198
34. Kater A.P., Dicker F., Mangiola M., Welsh K., Houghten R., Ostresh J., Nefzi A., Reed J.C., Pinilla C., and Kipps T.J. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 106 (2005) 1742-1748
35. Kater A.P., Evers L.M., Remmerswaal E.B., Jaspers A., Oosterwijk M.F., van Lier R.A., van Oers M.H., and Eldering E. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br. J. Haematol. 127 (2004) 404-415
36. Chu P., Deforce D., Pedersen I.M., Kim Y., Kitada S., Reed J.C., and Kipps T.J. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3854-3859
37. Gricks C.S., Zahrieh D., Zauls A.J., Gorgun G., Drandi D., Mauerer K., Neuberg D., and Gribben J.G. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 104 (2004) 4002-4009
38. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia (2008)
39. Labi V., Grespi F., Baumgartner F., and Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?. Cell Death Differ. 15 (2008) 977-987
40. Lajmanovich A., Irisarri M., Molens J.P., Pasquier M.A., Sotto J.J., Bensa J.C., Leroux D., and Plumas J. Impairment of death-inducing signalling complex formation in CD95-resistant human primary lymphoma B cells. Br. J. Haematol. 124 (2004) 746-753
41. Callanan M.B., Le Baccon P., Mossuz P., Duley S., Bastard C., Hamoudi R., Dyer M.J., Klobeck G., Rimokh R., Sotto J.J., and Leroux D. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 309-314
42. Fournier A., Florin A., Lefebvre C., Solly F., Leroux D., and Callanan M.B. Genetics and epigenetics of 1q rearrangements in hematological malignancies. Cytogenet. Genome Res. 118 (2007) 320-327
43. Izquierdo J.M., Majos N., Bonnal S., Martinez C., Castelo R., Guigo R., Bilbao D., and Valcarcel J. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol. Cell 19 (2005) 475-484
44. Martin D.A., Zheng L., Siegel R.M., Huang B., Fisher G.H., Wang J., Jackson C.E., Puck J.M., Dale J., Straus S.E., Peter M.E., Krammer P.H., Fesik S., and Lenardo M.J. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4552-4557
45. Barki-Celli L., Lefebvre C., Le Baccon P., Nadeau G., Bonnefoix T., Usson Y., Vourc'h C., Khochbin S., Leroux D., and Callanan M. Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements. Genes Chromosomes Cancer 43 (2005) 339-349
46. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-Lopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N.L., Armitage J.O., Carter W., Hoppe R., and Canellos G.P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17 (1999) 1244
47. Bonnal S., Martinez C., Forch P., Bachi A., Wilm M., and Valcarcel J. RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol. Cell 32 (2008) 81-95
48. Izquierdo J.M., and Valcarcel J. Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing. J. Biol. Chem. 282 (2007) 1539-1543
49. Castle J.C., Zhang C., Shah J.K., Kulkarni A.V., Kalsotra A., Cooper T.A., and Johnson J.M. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat. Genet. 40 (2008) 1416-1425
50. Pan Q., Shai O., Lee L.J., Frey B.J., and Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40 (2008) 1413-1415
51. Tai Y.T., Li X., Tong X., Santos D., Otsuki T., Catley L., Tournilhac O., Podar K., Hideshima T., Schlossman R., Richardson P., Munshi N.C., Luqman M., and Anderson K.C. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 65 (2005) 5898-5906
52. Law C.L., Gordon K.A., Collier J., Klussman K., McEarchern J.A., Cerveny C.G., Mixan B.J., Lee W.P., Lin Z., Valdez P., Wahl A.F., and Grewal I.S. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65 (2005) 8331-8338
53. O'Brien S.M., Claxton D.F., Crump M., Faderl S., Kipps T., Keating M.J., Viallet J., and Cheson B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113 (2009) 299-305
54. Hallaert D.Y., Jaspers A., van Noesel C.J., van Oers M.H., Kater A.P., and Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112 (2008) 5141-5149